Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Allergy Therapeutics ( (GB:AGY) ) just unveiled an update.
Allergy Therapeutics has issued 687,500,000 warrants for new ordinary shares as part of a £50 million loan facility agreement with SkyGem Acquisition Limited and Southern Fox Investments Limited. This issuance is significant for the company’s financial strategy, potentially impacting its market positioning by strengthening its capital structure and providing liquidity to support its operations and growth ambitions.
More about Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company based in the UK, focusing on the treatment and diagnosis of allergic disorders. The company specializes in developing aluminium-free immunotherapy vaccines, which have the potential to cure diseases. It distributes proprietary and third-party products across nine major European countries and through distribution agreements in ten additional countries.
YTD Price Performance: 13.23%
Average Trading Volume: 522,765
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £350.9M
Find detailed analytics on AGY stock on TipRanks’ Stock Analysis page.
